Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn


There's more to the US than tech stocks

James Gard  |  21 Aug 2020Text size  Decrease  Increase  |  
Email to Friend

The tech success story is an all-consuming one for investors, which reached further dizzying heights when Apple became the first listed company to reach a staggering valuation of $2 trillion.

The sector as a whole has been given a new lease of life by lockdown shopping, headlines about entrepreneurs such as Amazon founder Jezz Bezos’s $100 billion fortune and Apple’s bid to become the world’s first $2 trillion company. After such a strong run, seven tech stocks, including Facebook (FB.) and Microsoft (MSFT), now make up a quarter of the S&P 500 index. 

To many investors, it seems like tech is the only game in town - but there must surely be more the huge US market than technology. We’ve asked some US fund managers where they see the opportunities beyond the FAANGs.


US healthcare, how to fund it and who pays for it, has long been a contentious area and has made the investment case for the sector tough, particularly in election years. But coronavirus has changed the debate around healthcare completely, says Grant Bowers, manager of the Franklin US Opportunities Fund.

Regardless of who gets into the White House, he expects healthcare spending to rise and for that to wave to lift all boats. He is keen on medtech companies like California-based Edwards Lifesciences (EW), which makes artificial heart valves.

“Edwards remains the dominant force in surgical heart valves and minimally invasive valve therapy - one of the hottest areas in cardiac devices,” says Morningstar analyst Debbie Wang, who assigns the company a narrow moat because of its long history in pioneering technology and level of trust among heart surgeons.

Margaret Vitrano, co-portfolio manager of the four-star rated Legg Mason ClearBridge US Large Cap Growth Fund, says that compared to sectors like technology, “healthcare stocks remain attractively priced for the growth they deliver”. She believes there’s been a sea-change in attitude towards the sector: “There is growing sentiment that we need a thriving healthcare sector and companies that can invest in R&D to address unmet medical needs.”

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

She likes medical testing firm Thermo Fisher Scientific (TMO) and UnitedHealth Group (UNH), which offers a one-stop-shop including insurance and analytics. “The company's integrated strategy has resulted in some of the best returns in the industry in recent years,” says Morningstar analyst Julie Utterback, assigning UnitedHealth a narrow moat.

Vitrano also sees opportunities in pharmaceuticals and biotechnology, and favours genetic diseases specialist BioMarin Pharmaceutical (BMRN) and wide-moat biotech firm Amgen (AMGN).

Banks and payments

The financial sector is poised for change and disruption, says Bowers, who invests in Visa (V) and Mastercard (MC): "The rise of electronic payments has changed consumers' relationship with their money”. We have recently looked at how the Covid-19 crisis has accelerated the demise of cash, with Venmo-owner Paypal (PYPL) one of the main beneficiaries as people increasingly use smartphones to transfer small sums of money.

For Bowers, though, some of the most enticing opportunities involve streamlining investment bank processes, such as automating back office functions. He thinks bond trading is one of the areas that has so far lagged the technological revolution as it still relies on phone trading and person-to-person meeting.

Fintech firm MarketAxess (MKTX), meanwhile, offers electronic trading platforms and is set to disrupt this previously staid market, according to Bowers. Regulatory pressure on big banks is likely to increase the demand for transparency over trading, he adds.


While Amazon (AMZN) has been one of the obvious beneficiaries of the lockdown e-commerce boom, Vitrano is looking at the former bricks and mortar retailers that have been quick to adapt to the dramatic change in shopping habits have benefited. 

She points to wholesaler Costco (COST),which also has outlets in the UK, and is assigned a wide economic moat by Morningstar analysts. It now offers shoppers the chance to order online and pick up the goods without leaving their car. She also rates cosmetics retailer Ulta Beauty (ULTA), which offers a one-stop-shop for perfume, hairdressing products and makeup to retail and professional customers.

Despite the obvious challenges faced by the travel industry, she also likes certain names in the sector such as Booking.com, which should survive the current crisis. “The online travel agency has a variable cost structure and balance sheet to support them even if travel restrictions last several years,” she says.

Disruption is everywhere

The tech boom has undeniably triggered a domino effect that will affect all sectors in time. Bowers says the key will be finding companies across a range of industries that can shake-up their sector. “If we look out over the next decade, the big opportunities are going to come as this digital transformation wave sweeps through all the other industries," he says. The race for a Covid-19 vaccine is just one example of how quickly a sector, which was once staid and predictable, can change in response to a crisis.

With that in mind, he has been taking profits from his investments in the likes of Apple and Amazon and using the proceeds to increase his holdings in financial and healthcare stocks. “We are moving significantly faster than we ever have before,” he says. The lesson from tech, that huge leaps and bounds can be made in short time periods, has changed expectations for all industries.  

This article originally appeared on Morningstar.co.uk.

is senior editor for Morningstar.co.uk

© 2022 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend